Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cpp45335 ◽

2007 ◽

Vol 45 (06) ◽

pp. 335-344 ◽

Author(s):

W. Mueck ◽

M. Becka ◽

D. Kubitza ◽

B. Voith ◽

M. Zuehlsdorf

Keyword(s):

Population Model ◽

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects

Clinical Pharmacology in Drug Development ◽

10.1002/cpdd.232 ◽

2015 ◽

Vol 5 (1) ◽

pp. 13-26 ◽

Author(s):

Dawei Xuan ◽

Scott McBride ◽

Philip Wastall ◽

Anthony Porcari ◽

Lorenzo DiCarlo ◽

...

Keyword(s):

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor

The Journal of Clinical Pharmacology ◽

10.1002/jcph.5 ◽

2013 ◽

Vol 53 (3) ◽

pp. 249-255 ◽

Author(s):

Dagmar Kubitza ◽

Michael Becka ◽

Angelika Roth ◽

Wolfgang Mueck

Keyword(s):

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics ◽

Age And Gender ◽

Download Full-text

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery

Clinical Pharmacokinetics ◽

10.2165/00003088-200847030-00006 ◽

2008 ◽

Vol 47 (3) ◽

pp. 203-216 ◽

Author(s):

Wolfgang Mueck ◽

Bengt I Eriksson ◽

Kenneth A Bauer ◽

Lars Borris ◽

Ola E Dahl ◽

...

Keyword(s):

Population Pharmacokinetics ◽

Orthopaedic Surgery ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics ◽

Population Pharmacokinetics And Pharmacodynamics ◽

Major Orthopaedic Surgery

Download Full-text

Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects

The Journal of Clinical Pharmacology ◽

10.1177/0091270005281818 ◽

2006 ◽

Vol 46 (1) ◽

pp. 45-51 ◽

Author(s):

Anne Paccaly ◽

Annke Frick ◽

Marie-Laure Ozoux ◽

Valeria Chu ◽

Ronald Rosenburg ◽

...

Keyword(s):

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Download Full-text

Effect of Food, an Antacid, and the H2Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

The Journal of Clinical Pharmacology ◽

10.1177/0091270006286904 ◽

2006 ◽

Vol 46 (5) ◽

pp. 549-558 ◽

Author(s):

Dagmar Kubitza ◽

Michael Becka ◽

Michael Zuehlsdorf ◽

Wolfgang Mueck

Keyword(s):

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Download Full-text

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Journal of Cardiovascular Pharmacology ◽

10.1097/fjc.0b013e3182970991 ◽

2013 ◽

Vol 62 (2) ◽

pp. 212-221 ◽

Author(s):

Jeanne Mendell ◽

Frank Lee ◽

Shuquan Chen ◽

Valerie Worland ◽

Minggao Shi ◽

...

Keyword(s):

Factor Xa ◽

Antiplatelet Agents ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

British Journal of Clinical Pharmacology ◽

10.1111/bcp.12054 ◽

2013 ◽

Vol 76 (1) ◽

pp. 89-98 ◽

Author(s):

Dagmar Kubitza ◽

Angelika Roth ◽

Michael Becka ◽

Abir Alatrach ◽

Atef Halabi ◽

...

Keyword(s):

Single Dose ◽

Hepatic Impairment ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects

Journal of International Medical Research ◽

10.1177/030006051204000508 ◽

2012 ◽

Vol 40 (5) ◽

pp. 1688-1707 ◽

Author(s):

D Kubitza ◽

M Becka ◽

A Roth ◽

W Mueck

Keyword(s):

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Download Full-text

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

British Journal of Clinical Pharmacology ◽

10.1111/j.1365-2125.2009.03390.x ◽

2009 ◽

Vol 68 (1) ◽

pp. 77-88 ◽

Author(s):

Xia Zhao ◽

Peihong Sun ◽

Ying Zhou ◽

Yuwang Liu ◽

Huilin Zhang ◽

...

Keyword(s):

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacokinetics And Pharmacodynamics ◽

Multiple Doses ◽

Healthy Chinese ◽

Chinese Subjects

Download Full-text

PHARMACODYNAMIC INTERACTION BETWEEN TAK-442, AN ORAL DIRECT FACTOR XA INHIBITOR, AND PRASUGREL IN HEALTHY SUBJECTS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(11)61504-0 ◽

2011 ◽

Vol 57 (14) ◽

pp. E1504

Author(s):

Nolan Wood ◽

Fran Stringer ◽

Ruishan Wu ◽

Masaki Kawamura ◽

Jeff Spaeder

Keyword(s):

Healthy Subjects ◽

Factor Xa ◽

Factor Xa Inhibitor ◽

Direct Factor ◽

Pharmacodynamic Interaction

Download Full-text